Galectin Therapeutics, Inc. (NASDAQ: GALT) Starts Presentation at 30th Annual ROTH Conference
Galectin Therapeutics (NASDAQ: GALT) is a biotechnology company focused on the discovery and development and new therapies to improve the lives of patients with chronic liver and skin diseases and cancer. The company is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of directly involved in multiple inflammatory, fibrotic, and malignant diseases. Drug candidates based on the company’s unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function. Galectin Therapeutics’ lead development program is in non-alcoholic steatohepatitis (“NASH”) with cirrhosis, the most advanced form of NASH related fibrosis. Further…







